Related Experiment Videos
Single-dose dacarbazine and dactinomycin in advanced malignant melanoma
Cancer Treatment Reports
|January 1, 1985
Summary
This study shows that combining dacarbazine and dactinomycin chemotherapy is a safe and effective treatment for advanced malignant melanoma. The combination therapy achieved a 22% response rate, with complete responses observed in patients with visceral disease.
Area of Science:
- Oncology
- Medical research
Background:
- Advanced malignant melanoma presents a significant therapeutic challenge.
- Evaluating novel chemotherapy regimens is crucial for improving patient outcomes.
Observation:
- Twenty-one patients with advanced malignant melanoma received dacarbazine (800 mg/m2) and dactinomycin (1.2 mg/m2) every 3 weeks.
- Treatment was generally well-tolerated, with mild hematologic and tolerable gastrointestinal toxicity.
Findings:
- The overall response rate was 22% among evaluable patients, including those with visceral metastases.
- Three of the four responses were complete, with durations ranging from 4 to over 48 months.
Implications:
- Dacarbazine and dactinomycin combination therapy is a safe and effective option for advanced melanoma.
- Further research is warranted to explore the potential of this combination for achieving complete responses in patients with visceral disease.